OPEN END TURBO LONG - ELI LILLY & CO | Real-time Bid/Ask 12:20:58 12/07/2024 pm IST | ||
| 56.63 EUR / 56.87 EUR | +0.50% |
|
| Current month | +1.77% | ||
| 1 month | +5.67% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 12/24/12 | 56.47 | -2.03% |
| 10/24/10 | 57.64 | +1.55% |
| 09/24/09 | 56.76 | +2.31% |
| 08/24/08 | 55.48 | +0.45% |
| 05/24/05 | 55.23 | +1.99% |
Delayed Quote Börse Stuttgart
Last update July 12, 2024 at 12:38 am IST
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | Morgan Stanley |
| WKN | MB2U4U |
| ISIN | DE000MB2U4U1 |
| Date issued | 26/01/2023 |
| Strike | 317.3 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 6.16 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 57.79 € |
|---|---|
| Lowest since issue | 2.73 € |
| Spread | 0.24 € |
| Spread % | 0.42% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
934.1
USD
Average target price
887.2
USD
Spread / Average Target
-5.03%
- Stock Market
- Certificates
- Certificat
